Approval

Gevalka Approved in EU

The European Commission approved Gevalka for adults with ALK-positive advanced non-small cell lung cancer. The approval was based on the phase 3 eXalt3 study, in which median progression-free survival was 25.8 months with ensartinib versus 12.7 months in the control group. Betta and its subsidiary Xcovery developed ensartinib, which has also been approved in China and the United States; an exclusive licensing agreement with Mankind Pharma covers India.

Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call